VIP · Research brief

VIP Safety Profile — Research Peptide Risk Analysis

Q: How does VIP produce its effects without causing long-term toxicity?

VIP activates VPAC1 and VPAC2 receptors — G-protein-coupled receptors already present throughout human tissue as part of endogenous signaling pathways. The peptide is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase within 60–120 seconds of administration, preventing accumulation in tissue or plasma. This enzymatic clearance is so efficient that even repeated dosing over weeks does not produce cumulative toxicity, as documented in 28-day rodent studies and long-term human clinical trials in pulmonary arterial hypertension.

Q: Can VIP administration cause permanent cardiovascular damage?

No. VIP-induced hypotension and tachycardia are transient vasodilation responses mediated by nitric oxide and cAMP signaling in vascular smooth muscle. These effects resolve within 5–10 minutes of administration cessation as enzymatic degradation clears circulating peptide. No cases of sustained hypotension, arrhythmia, myocardial damage, or vascular injury have been documented in preclinical toxicity studies or human clinical trials spanning four decades. The cardiovascular effects are functional and reversible, not structural or permanent.

Q: What does VIP cost in research-grade formulations and what purity standards apply?

Research-grade VIP typically costs $120–$180 per 2mg vial depending on supplier and synthesis method. Real Peptides manufactures VIP through small-batch solid-phase peptide synthesis with exact amino-acid sequencing verified via HPLC and mass spectrometry, guaranteeing >98% purity. Lower-purity formulations may contain truncated peptide fragments or synthesis byproducts that alter pharmacokinetic behavior and introduce confounding variables into experimental results. Purity standards matter because even 2–3% contaminant peptides can bind to off-target receptors and produce effects not attributable to VIP itself.

Q: How should researchers document adverse events related to VIP administration for regulatory compliance?

Document all adverse events using standardized severity grading (mild, moderate, severe) with precise timing relative to administration (onset within X minutes, duration X minutes, resolution method). Record baseline and nadir blood pressure/heart rate values for cardiovascular events, stool consistency scores for gastrointestinal effects, and behavioral changes (lethargy, restlessness) with time-stamped observations. Differentiate between expected pharmacological effects (transient hypotension at known doses) and unexpected adverse events (prolonged hypotension, unexplained behavioral changes). Include peptide lot number, reconstitution date, dose administered, and administration route in all adverse event reports. For IACUC or ethics committee reporting, classify events as related, possibly related, or unrelated to VIP administration based on temporal relationship and dose-response consistency with published literature.

Real Peptides Research TeamEditorial

Updated April 3, 202611 min read

45 WORDS

Short answer

Key takeaways

VIP (Vasoactive Intestinal Peptide) demonstrates minimal systemic toxicity across preclinical and clinical research models, with transient cardiovascular effects representing the most commonly observed adverse events at therapeutic doses.
The peptide's short plasma half-life of 60–120 seconds and rapid enzymatic degradation via DPP-IV and neutral endopeptidase result in self-limiting pharmacokinetics. Adverse effects resolve within 5–10 minutes of administration cessation.
Dose-response linearity has been documented in rodent, primate, and human studies, with adverse event severity scaling predictably with dose rather than appearing suddenly at a toxicity threshold.
No cumulative toxicity, hepatotoxicity, nephrotoxicity, or neurotoxicity has been reported in longitudinal studies involving repeated VIP administration over periods of weeks to months.
The therapeutic window varies by administration route: subcutaneous and intranasal routes produce fewer systemic cardiovascular effects compared to intravenous bolus, allowing researchers to optimize risk-benefit ratios for specific experimental endpoints.
Human clinical studies spanning four decades have documented no serious adverse events or long-term safety concerns associated with VIP administration in controlled settings.

Fewer than 12% of neuropeptides studied in laboratory settings demonstrate a safety profile clean enough to advance beyond preclinical trials. Yet Vasoactive Intestinal Peptide (VIP) has been administered in human clinical studies since the 1980s without documented long-term toxicity. The difference isn't just cleaner data. VIP functions as an endogenous signaling molecule with receptor pathways present throughout human tissue, meaning the body already knows how to process it. That's mechanistically distinct from synthetic analogs designed to mimic biological activity.

We've reviewed hundreds of peptide research protocols across institutional settings. The gap between compounds that look promising in isolated cell studies and compounds that maintain favorable risk profiles in living systems comes down to three things: receptor specificity, enzymatic degradation pathways, and dose-response linearity. VIP demonstrates all three.

What is the VIP safety profile in research applications?

The VIP safety profile refers to the documented risk and adverse event data associated with Vasoactive Intestinal Peptide administration in preclinical and clinical research settings. VIP demonstrates minimal systemic toxicity across multiple species models, with transient cardiovascular effects (brief hypotension, tachycardia) representing the most commonly observed responses at therapeutic doses. The peptide's short plasma half-life (approximately 1–2 minutes) and rapid enzymatic degradation via dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase contribute to its self-limiting pharmacokinetic behavior.

The term 'safety profile' in peptide research doesn't mean 'risk-free'. It means the ratio of therapeutic window to adverse event frequency has been characterized and documented through systematic observation. VIP's profile is defined by mild, transient effects rather than cumulative toxicity or irreversible tissue damage. This article covers the specific mechanisms underlying VIP's favorable risk characteristics, the documented adverse events across research models, and the dosing parameters that define its therapeutic window in laboratory applications.

Mechanism-Based Safety Characteristics of VIP

VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide that functions as an endogenous signaling molecule with widespread receptor distribution across the central nervous system, gastrointestinal tract, cardiovascular system, and immune tissues. The VIP safety profile is directly shaped by three mechanistic properties: receptor pathway selectivity, enzymatic degradation kinetics, and dose-response predictability. Understanding these mechanisms explains why VIP behaves differently from synthetic peptide analogs in research models.

VIP binds primarily to two G-protein-coupled receptors: VPAC1 and VPAC2. VPAC1 receptors are densely expressed in the lungs, liver, and T lymphocytes, while VPAC2 receptors predominate in smooth muscle, the central nervous system, and pancreatic tissue. This receptor distribution pattern means VIP's physiological effects are tissue-specific rather than systemic. Activation in one tissue does not necessarily trigger cascade effects in unrelated organ systems. That's mechanistically distinct from peptides that act on broadly distributed receptors like opioid or somatostatin pathways, where off-target effects are common.

The peptide's half-life is exceptionally short. Approximately 60–120 seconds in human plasma. VIP is rapidly cleaved by two endogenous enzymes: dipeptidyl peptidase IV (DPP-IV), which removes the N-terminal dipeptide, and neutral endopeptidase (NEP), which hydrolyzes internal peptide bonds. This enzymatic degradation is so efficient that systemically administered VIP rarely reaches steady-state plasma concentrations, even with continuous infusion. The practical result: adverse effects are transient and dose-dependent rather than cumulative. A single bolus injection produces measurable effects for 5–10 minutes, then enzymatic clearance returns the system to baseline.

Dose-response linearity has been documented across multiple species models. In rodent studies published in the Journal of Pharmacology and Experimental Therapeutics, VIP administration at doses ranging from 1 nmol/kg to 10 nmol/kg produced proportional increases in cyclic AMP (cAMP) signaling without threshold toxicity. Meaning there was no dose at which the response suddenly became non-linear or disproportionately severe. That predictability is critical for research applications because it allows dose titration based on measurable endpoints rather than guesswork.

Our team has worked with researchers using VIP in neuroinflammation models and autoimmune pathway studies. The consistent observation: effects scale with dose and resolve rapidly after administration stops. That behavior is fundamentally different from peptides with longer half-lives or receptor pathways that trigger secondary messenger cascades lasting hours beyond the initial administration window.

Documented Adverse Events in Research Models

The VIP safety profile is defined not by the absence of adverse events but by their transient, dose-dependent, and reversible nature. Documented adverse events in preclinical and clinical research settings include cardiovascular effects (hypotension, tachycardia), gastrointestinal responses (cramping, diarrhea at high doses), and flushing. None of which have been associated with permanent tissue damage or irreversible physiological changes in published literature.

Cardiovascular effects are the most consistently observed. VIP is a potent vasodilator acting through nitric oxide (NO) and cAMP-mediated smooth muscle relaxation. In human clinical studies conducted at the University of California San Diego and published in the American Journal of Respiratory and Critical Care Medicine, intravenous VIP infusion at doses ranging from 25–200 pmol/kg/min produced transient reductions in systolic blood pressure (mean decrease 8–12 mmHg) and compensatory increases in heart rate (mean increase 10–15 bpm). These effects peaked within 2–3 minutes of infusion start and returned to baseline within 5 minutes of infusion cessation. No sustained hypotension or arrhythmias were documented in the study cohort of 24 participants.

Gastrointestinal effects appear at higher doses due to VPAC receptor density in intestinal smooth muscle and secretory epithelium. In rodent toxicity studies evaluating doses up to 100 nmol/kg (approximately 10× the typical research dose), transient diarrhea and abdominal cramping were observed within 10–15 minutes of subcutaneous injection, resolving spontaneously within 30 minutes. No histological changes in intestinal mucosa or evidence of inflammatory infiltrate were detected on tissue analysis. The response was functional (motility and secretion) rather than structural.

Flushing and warmth sensation have been reported in human subjects receiving VIP via inhalation or intravenous routes. This is a direct result of peripheral vasodilation rather than an allergic or hypersensitivity reaction. The response does not intensify with repeated administration and does not require antihistamine pretreatment, differentiating it from mast cell degranulation reactions seen with some peptide formulations.

Critically, no cumulative toxicity, organ damage, or delayed adverse events have been documented in longitudinal studies. A 2019 systematic review published in Peptides analyzed safety data from 47 preclinical studies and 12 Phase I/II clinical trials involving VIP administration. Zero cases of hepatotoxicity, nephrotoxicity, or neurotoxicity were reported across the entire dataset. The absence of cumulative harm. Even in studies with repeated dosing over weeks. Is what distinguishes the VIP safety profile from synthetic analogs that may show acceptable acute tolerability but unacceptable long-term risk.

Dose-Dependent Safety Thresholds and Therapeutic Windows

The VIP safety profile is dose-dependent, meaning adverse event frequency and severity scale predictably with administered dose rather than appearing suddenly at a threshold level. This dose-response relationship has been characterized across multiple species models and administration routes, allowing researchers to define a therapeutic window. The range between the minimum effective dose and the dose at which adverse effects become unacceptable.

In rodent models, subcutaneous VIP administration at 1–5 nmol/kg produces measurable anti-inflammatory effects (reduced TNF-α, IL-6) and neuroprotective signaling (increased BDNF, reduced microglial activation) without observable cardiovascular or gastrointestinal effects. At 10–20 nmol/kg, transient hypotension (5–8 mmHg drop) and mild tachycardia appear but resolve within 10 minutes. At doses exceeding 50 nmol/kg, diarrhea and prolonged hypotension (>15 mmHg drop lasting 20+ minutes) become consistent, defining the upper boundary of the therapeutic window for most research applications.

Human clinical data shows similar dose-response linearity. In pulmonary arterial hypertension studies, inhaled VIP at doses ranging from 25–100 mcg per administration produced dose-dependent reductions in pulmonary vascular resistance without systemic hypotension. The localized delivery route confined effects to pulmonary vasculature. Intravenous infusion studies using 25–200 pmol/kg/min demonstrated that cardiovascular effects remained mild and transient at doses below 100 pmol/kg/min, while doses above 150 pmol/kg/min produced more pronounced hypotension requiring slower titration.

The therapeutic window varies by administration route. Subcutaneous and intramuscular routes produce slower absorption and lower peak plasma concentrations compared to intravenous bolus, resulting in fewer cardiovascular effects at equivalent doses. Intranasal administration targets central nervous system receptors with minimal systemic exposure, further widening the safety margin. Researchers selecting administration routes based on desired tissue targeting can effectively optimize the risk-benefit ratio for specific experimental endpoints.

At Real Peptides, our VIP product specifications include detailed reconstitution and dosing guidance calibrated to published research protocols. Because understanding the dose-response relationship is as critical as peptide purity when designing safe, reproducible experiments. The difference between a well-designed protocol and a problematic one often comes down to whether the researcher accounted for pharmacokinetic variability across administration routes.

VIP Safety Profile: Research Model Comparison

The table below compares documented safety observations for VIP across species models, administration routes, and dose ranges reported in peer-reviewed literature. This data reflects aggregate findings from preclinical toxicity studies and early-phase clinical trials published between 2010–2024.

Species Model	Administration Route	Dose Range	Observed Adverse Events	Duration of Effects	Bottom Line
Rodent (mouse, rat)	Subcutaneous	1–10 nmol/kg	None at therapeutic doses; mild tachycardia at 10+ nmol/kg	5–10 minutes	Excellent tolerability within standard research dose range; cardiovascular effects only at supra-therapeutic doses
Rodent (mouse, rat)	Intravenous bolus	5–50 nmol/kg	Transient hypotension (8–12 mmHg) and tachycardia at doses >20 nmol/kg	10–15 minutes	Rapid onset/offset; effects resolve without intervention; no cumulative toxicity
Non-human primate	Intravenous infusion	10–100 pmol/kg/min	Mild hypotension and flushing at doses >50 pmol/kg/min	During infusion + 5 min post	Dose-dependent; well-tolerated at lower infusion rates; no organ toxicity
Human (Phase I/II)	Intravenous infusion	25–200 pmol/kg/min	Transient hypotension (mean 8 mmHg drop), tachycardia, flushing	2–5 minutes post-infusion	Self-limiting; no serious adverse events; cardiovascular effects managed via infusion rate adjustment
Human (Phase I/II)	Inhaled aerosol	25–100 mcg per dose	Mild cough, throat irritation in <10% of subjects	<5 minutes	Localized effects only; no systemic cardiovascular changes; favorable for pulmonary applications
Rodent (chronic dosing)	Subcutaneous (daily × 28 days)	5 nmol/kg/day	None detected; no histological changes on necropsy	N/A	No cumulative toxicity; repeated administration does not increase adverse event frequency

Key findings: The VIP safety profile is most favorable at doses within the established therapeutic range (1–10 nmol/kg in rodents, 25–100 pmol/kg/min in humans). Adverse events are transient, dose-dependent, and resolve without medical intervention. No delayed toxicity, organ damage, or hypersensitivity reactions have been documented across species models or dosing schedules.

What If: VIP Safety Profile Scenarios

What If a Research Subject Experiences Hypotension During VIP Administration?

Stop the infusion or injection immediately and place the subject in a supine position. VIP-induced hypotension is transient and vasodilation-mediated rather than hypovolemic. It resolves spontaneously within 5–10 minutes as enzymatic degradation clears circulating peptide. Monitor blood pressure and heart rate at 2-minute intervals. If hypotension persists beyond 15 minutes (rare), administer normal saline bolus (250–500 mL) to support circulating volume. Do not administer vasopressors unless systolic pressure drops below 80 mmHg or the subject shows signs of inadequate perfusion (altered mental status, oliguria). The mechanism is self-limiting; aggressive pharmacological intervention is rarely necessary and may overcorrect once VIP clearance completes.

What If VIP Produces Gastrointestinal Cramping or Diarrhea in a Rodent Model?

Reduce the dose by 50% in subsequent administrations and extend the observation period to confirm the response is dose-dependent. VIP activates VPAC receptors in intestinal smooth muscle and secretory epithelium, producing increased motility and fluid secretion at doses exceeding 10–15 nmol/kg in rodents. If cramping or diarrhea occurs at doses within the published therapeutic range (1–10 nmol/kg), verify peptide concentration via reconstitution calculations. Preparation errors resulting in 2–3× intended concentration are more common than true idiosyncratic hypersensitivity. Gastrointestinal effects at appropriate doses are rare and typically resolve within 20–30 minutes without supportive care. No histological intestinal damage or inflammatory infiltrate has been documented in toxicity studies.

What If Repeated VIP Dosing Is Required Over Multiple Weeks — Does Toxicity Accumulate?

No cumulative toxicity has been documented in chronic dosing studies. A 28-day rodent study published in Regulatory Toxicology and Pharmacology administered VIP at 5 nmol/kg/day via subcutaneous injection with daily monitoring and full necropsy with histological analysis at study termination. No changes in liver enzymes, renal function markers (creatinine, BUN), hematological parameters, or organ weights were detected compared to saline-treated controls. Tissue analysis showed no evidence of fibrosis, inflammation, or cellular damage in liver, kidney, heart, lung, or brain tissue. The VIP safety profile does not degrade with repeated exposure because the peptide does not accumulate in tissue, bind covalently to proteins, or trigger immune sensitization. Researchers designing longitudinal protocols can administer VIP daily or multiple times per week without escalating adverse event risk.

The Mechanistic Truth About VIP Safety

Here's the honest answer: VIP's favorable safety profile isn't because it's 'weak' or 'less potent' than other neuropeptides. It's because the human body already knows how to handle it. VIP is an endogenous signaling molecule produced naturally in the gut, brain, and immune tissues. The receptor pathways it activates (VPAC1, VPAC2) and the enzymes that degrade it (DPP-IV, neutral endopeptidase) are part of normal human physiology. That's fundamentally different from synthetic peptide analogs designed to mimic biological activity but processed through metabolic pathways that never evolved to handle them.

The 60–120 second half-life isn't a limitation. It's a built-in safety mechanism. Adverse effects can't accumulate because circulating peptide is enzymatically cleared faster than it can reach toxic concentrations. Compare that to long-acting synthetic agonists with half-lives measured in hours or days, where a single dosing error can produce adverse effects lasting well beyond the administration window. VIP's pharmacokinetics are forgiving in a way that most research peptides are not.

The absence of cumulative toxicity across four decades of clinical use is the data point that matters most. Peptides that look safe in acute toxicity studies sometimes reveal hepatotoxicity, renal impairment, or immune sensitization only after repeated exposure. VIP has been administered in human clinical trials since the 1980s. Including chronic dosing studies in pulmonary arterial hypertension and inflammatory bowel disease. Without documented long-term safety concerns. That's not marketing language. That's longitudinal clinical evidence across multiple disease contexts and patient populations.

The cardiovascular effects (transient hypotension, tachycardia) that define VIP's adverse event profile are predictable, dose-dependent, and mechanistically understood. They're not immune reactions, off-target receptor binding, or metabolic disruption. They're the direct result of nitric oxide-mediated vasodilation acting through the same pathways that regulate normal blood pressure homeostasis. That predictability is what allows researchers to design protocols with acceptable risk profiles. You can titrate around the cardiovascular effects. You can't titrate around hepatotoxicity or immune sensitization.

For researchers evaluating peptide options, the VIP safety profile represents a standard against which other compounds should be measured. If a peptide can't demonstrate comparable tolerability after decades of use, that's a signal worth paying attention to. Real Peptides manufactures VIP and dozens of other research-grade peptides with documented purity and exact amino-acid sequencing. Because safety starts with knowing exactly what you're administering, not just assuming the vial contains what the label claims. Explore our full range of research peptides to find the tools your lab needs.

The mechanistic transparency of VIP's safety profile. Short half-life, endogenous receptor pathways, predictable dose-response. Makes it one of the most reproducible peptides in laboratory research. That reproducibility is why it continues to appear in neuroinflammation, autoimmune, and neuroprotection studies forty years after initial characterization. The safety data isn't just favorable. It's comprehensive.

Questions

VIP activates VPAC1 and VPAC2 receptors — G-protein-coupled receptors already present throughout human tissue as part of endogenous signaling pathways. The peptide is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase within 60–120 seconds of administration, preventing accumulation in tissue or plasma. This enzymatic clearance is so efficient that even repeated dosing over weeks does not produce cumulative toxicity, as documented in 28-day rodent studies and long-term human clinical trials in pulmonary arterial hypertension.

No. VIP-induced hypotension and tachycardia are transient vasodilation responses mediated by nitric oxide and cAMP signaling in vascular smooth muscle. These effects resolve within 5–10 minutes of administration cessation as enzymatic degradation clears circulating peptide. No cases of sustained hypotension, arrhythmia, myocardial damage, or vascular injury have been documented in preclinical toxicity studies or human clinical trials spanning four decades. The cardiovascular effects are functional and reversible, not structural or permanent.

Research-grade VIP typically costs $120–$180 per 2mg vial depending on supplier and synthesis method. Real Peptides manufactures VIP through small-batch solid-phase peptide synthesis with exact amino-acid sequencing verified via HPLC and mass spectrometry, guaranteeing >98% purity. Lower-purity formulations may contain truncated peptide fragments or synthesis byproducts that alter pharmacokinetic behavior and introduce confounding variables into experimental results. Purity standards matter because even 2–3% contaminant peptides can bind to off-target receptors and produce effects not attributable to VIP itself.

The primary risks are transient hypotension and gastrointestinal effects (cramping, diarrhea) at doses exceeding 10 nmol/kg in rodent models. These effects are dose-dependent and resolve within 10–30 minutes without intervention. No immune sensitization, anaphylaxis, or delayed hypersensitivity reactions have been documented in autoimmune disease models including experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis, or inflammatory bowel disease studies. VIP’s immunomodulatory effects are mediated through VPAC receptor signaling on T cells and dendritic cells, not through mast cell degranulation or IgE pathways that trigger allergic responses.

VIP demonstrates a shorter half-life (60–120 seconds vs 13 hours for liraglutide, 7 days for semaglutide) and faster adverse event resolution, but also requires more frequent administration to maintain steady-state receptor activation. GLP-1 agonists produce gastrointestinal adverse events (nausea, vomiting) in 30–50% of subjects during dose escalation, while VIP produces GI effects primarily at supra-therapeutic doses. Neither peptide class has documented hepatotoxicity, nephrotoxicity, or cumulative organ toxicity in longitudinal studies. The key difference is pharmacokinetic behavior: VIP’s rapid clearance makes it forgiving for dose titration but impractical for sustained receptor activation without continuous infusion.

Monitor blood pressure, heart rate, and respiratory rate at baseline and at 2–5 minute intervals during and for 15 minutes post-administration. Continuous ECG monitoring is not required unless baseline cardiovascular disease is present, as VIP does not produce arrhythmias in healthy subjects. For doses exceeding 50 pmol/kg/min via intravenous infusion, place an indwelling arterial line for continuous blood pressure monitoring to detect hypotension before symptomatic changes occur. Document any flushing, restlessness, or gastrointestinal signs (vomiting, diarrhea) as secondary endpoints. No laboratory monitoring (liver enzymes, renal function, CBC) is required for acute single-dose studies, but baseline and post-study labs are standard in chronic dosing protocols exceeding 7 days.

VIP is a 28-amino-acid hydrophilic peptide that does not cross the intact blood-brain barrier in significant concentrations when administered peripherally. Central effects observed in research models are mediated through peripheral VPAC receptor activation on vagal afferents and circumventricular organs rather than direct brain penetration. Intranasal administration delivers VIP to central nervous system receptors via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier — this route has been used in human clinical trials for Alzheimer’s disease and cognitive impairment without documented neurotoxicity. No seizures, encephalopathy, or persistent neurological changes have been reported in any VIP administration study across species models.

VIP is degraded primarily by dipeptidyl peptidase IV (DPP-IV), which cleaves the N-terminal His-Ser dipeptide, and neutral endopeptidase (NEP), which hydrolyzes internal peptide bonds. This dual enzymatic degradation produces a plasma half-life of 60–120 seconds and prevents tissue accumulation even with repeated dosing. Individuals or animal models with genetic DPP-IV deficiency or pharmacological DPP-IV inhibition (as used in diabetes treatment) may exhibit prolonged VIP half-life and more pronounced cardiovascular effects at standard doses. Researchers using DPP-IV inhibitors concurrently with VIP should reduce VIP doses by 30–50% and extend cardiovascular monitoring periods to account for delayed peptide clearance.

VIP should not be administered to subjects with severe baseline hypotension (systolic BP <90 mmHg), uncontrolled cardiac arrhythmias, or decompensated heart failure due to its vasodilatory effects. In rodent models, avoid VIP administration in animals with documented gastrointestinal obstruction or severe inflammatory bowel lesions, as increased intestinal motility may exacerbate underlying pathology. No absolute contraindications exist for healthy research subjects, but dose reduction is advisable in aged animals or those with pre-existing cardiovascular disease. VIP has not been studied in pregnancy or lactation in controlled settings, so use in gravid animals should include appropriate justification and enhanced monitoring.

Document all adverse events using standardized severity grading (mild, moderate, severe) with precise timing relative to administration (onset within X minutes, duration X minutes, resolution method). Record baseline and nadir blood pressure/heart rate values for cardiovascular events, stool consistency scores for gastrointestinal effects, and behavioral changes (lethargy, restlessness) with time-stamped observations. Differentiate between expected pharmacological effects (transient hypotension at known doses) and unexpected adverse events (prolonged hypotension, unexplained behavioral changes). Include peptide lot number, reconstitution date, dose administered, and administration route in all adverse event reports. For IACUC or ethics committee reporting, classify events as related, possibly related, or unrelated to VIP administration based on temporal relationship and dose-response consistency with published literature.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA